PLX5622
| Catalog Number | Pack Size | List Price* | Promo Price* | Quantity | |
|---|---|---|---|---|---|
| HY-114153-5MG | 5 mg | 144,00 | 89,30 | Add | |
| HY-114153-1ML | 10mM/1mL | 155,00 | 96,10 | Add | |
| HY-114153-10MG | 10 mg | 222,00 | 137,70 | Add | |
| HY-114153-25MG | 25 mg | 420,00 | 260,40 | Add | |
| HY-114153-50MG | 50 mg | 692,00 | 429,10 | Add | |
| HY-114153-100MG | 100 mg | 1'034,00 | 641,10 | Add | |
| HY-114153-500MG | 500 mg | 1'983,00 | 1'229,50 | Add | |
| HY-114153-S-1ST | Sample | Inquire |
* CHF, excl. 8.1% VAT and shipping costs
Product Description
Promotion runs until 31.12.2026Best price guarantee – we offer you the lowest price in Switzerland. Please contact us for a quote if needed.
PLX5622 is a highly selective brain penetrant and orally active CSF1R inhibitor (IC50=0.016 μM; Ki=5.9 nM) . PLX5622 allows for extended and specific microglial cells elimination, preceding and during pathology development. PLX5622 demonstrates desirable PK properties in varies animals. PLX5622 is predominantly administered via ad libitum diets with a dose of 1200 ppm[1][2].
| Category | Biochemicals |
| Supplier | MedChem Express |
| Regulatory Status | RUO |
| Research Field | Neurological Disease |
| Format | Solubility: DMSO : 50 mg/mL (ultrasonic) ;Ethanol : 3.33 mg/mL (ultrasonic;warming;heat to 60°C) ;H2O : < 0.1 mg/mL |
| Grade | Clinical information: Phase 1 |
| Purity | 99.95% |
| Molecular Formula | C21H19F2N5O |
| Molecular Weight | 395.41 |
| CAS-Number | 1303420-67-8 |
| Storage Conditions | -20°C, 3 years; 4°C, 2 years (Powder) |
| Tech. Data Sheet | View datasheet |
| Link To Supplier | http://www.medchemexpress.com |
| Shipping Details | Room Temperature |
| Material Safety Data Sheet | Download PDF |
